• Mashup Score: 0

    s of 76 patients who underwent bilateral cataract surgeries were enrolled in this study. The surgical method was randomly assigned to each patient’s eye (1 eye using the illuminated chopper with a light source and the other using the conventional chopper under the microscope light). Patient suffering scores (the degree of strong light perception, glare, inability to fixate, anxiety, discomfort, and fear) from 0 to 10 (10 being the most severe level); cooperation score from 0 to 3 (3 being the best cooperation); operating time; and corneal endothelial cell density (ECD) preoperatively and postoperatively were compared between the 2 groups. Results: The mean patient suffering score of all 6 parameters in the iChopper group was significantly smaller than those in the control group (all P < .05). The mean patient cooperation score of the iChopper group (2.3 ± 0.8) was significantly greater than that of the control (1.6 ± 0.9; P < .001). There was no significant difference in the mean opera

    Tweet Tweets with this article
    • This open article and associated video compares patient experiences and cooperation and the clinical outcomes illuminated chopper vs conventional chopper during #CataractSurgery. Read more: https://t.co/veFtHl2M9J  #Ophthalmology #Ophthalmologist #EyeSurgery #EyeSurgeon https://t.co/iCmbBKVHVX

  • Mashup Score: 0

    D espite LASIK’s accuracy, enhancements simply come with the territory. E very once in a while a target is missed or a patient from years ago will show up with visual complaints and refractive surgeons must consider time, technique and potential risks of retreatment. We asked some veteran refractive surgeons for their insight and pearls for these rare but unavoidable situations. Enhancements typically fall into two categories: early and late. Early enhancements take place within the first few months of

    Tweet Tweets with this article
    • LASIK Enhancements: Handle with Care Refractive surgeons say the keys to managing these cases are patience and precision. https://t.co/c6k5HV4Hfw #ophthalmology #eyecare #eyesurgeon #eyesurgery #LASIK #refractivesurgery #ophthalmologist #vision https://t.co/08OpJQfK7o

  • Mashup Score: 0

    Bausch + Lomb announced the US commercial launch of MIEBO (perfluorohexyloctane ophthalmic solution) for the treatment of the signs and symptoms of dry eye disease (DED). MIEBO is the first prescription eyedrop approved for DED that directly targets tear evaporation. MIEBO is a single ingredient, water-, preservative- and steroid-free prescription eyedrop designed to address the signs and symptoms of DED by reducing tear evaporation at the ocular surface. The FDA approved MIEBO in May 2023, based on

    Tweet Tweets with this article
    • Quick Notes from the Week: Bausch + Lomb announced the US commercial launch of MIEBO for DED; Novartis discontinued the development of its GA gene therapy candidate GT005; and more. https://t.co/siYRkiKczw. #ophthalmologist #ophthalmology #youngophthalmologists #eyecare https://t.co/nBCDlqgHqk

  • Mashup Score: 0
    Tweet Tweets with this article
    • Just 1 hour to go before we commence the JCRS Symposium! Join us in Room C2 at #ESCRS2023 to hear more on controversies in anterior segment surgery. We hope to see you there! Find out more: https://t.co/shJH2rWS6B  #Ophthalmology #Ophthalmologist #EyeSurgery #EyeSurgeon https://t.co/tOfxsR28w0